Pediatric Asthma Treatment Market Report 2025

The pediatric asthma treatment market size has grown strongly in recent years. It will grow from $11.03 billion in 2024 to $11.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to the increasing incidence of childhood asthma, heightened awareness of respiratory disorders in children, a rise in air pollution and environmental allergens, growing healthcare spending on pediatric care, and awareness campaigns led by NGOs and healthcare organizations focused on asthma.

The pediatric asthma treatment market size is expected to see strong growth in the next few years. It will grow to $14.39 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth projected for the forecast period can be attributed to the rising prevalence of allergic disorders in children, the expansion of biologic therapies for severe pediatric asthma, increased investments in pediatric drug development, a growing focus on personalized and precision medicine, and the expanding middle-class population with access to private healthcare. Key trends expected during this period include the development of pediatric-friendly biologic therapies, creation of rapid allergen identification tools, integration of electronic health records, innovations in inhaler formulations, and advances in immunotherapy for asthma.

The rising prevalence of respiratory infections is expected to drive growth in the pediatric asthma treatment market going forward. Respiratory infections are illnesses caused by viruses, bacteria, or other pathogens that impact the respiratory tract, including the nose, throat, airways, and lungs. This increase is mainly attributed to rising air pollution, as exposure to pollutants like particulate matter and nitrogen dioxide weakens the respiratory system, making individuals more vulnerable to infections. Pediatric asthma treatments help reduce the frequency and severity of respiratory infections by improving airway function and decreasing inflammation, thereby lowering susceptibility to infectious triggers. For example, according to the Australian Institute of Health and Welfare, a government agency in Australia, chronic obstructive pulmonary disease accounted for 3.6% of the total disease burden and represented 50% of the total burden of respiratory conditions in 2023. Additionally, an estimated 638,000 people (2.5% of the population) in Australia were living with chronic obstructive pulmonary disease in 2022. Hence, the rising incidence of respiratory infections is fueling the growth of the pediatric asthma treatment market.

Key companies in the pediatric asthma treatment market are focusing on innovative therapies, such as monoclonal antibodies, to target and reduce airway inflammation in children. Monoclonal antibodies are laboratory-produced proteins designed to mimic the immune system’s ability to combat harmful pathogens by specifically targeting certain cells or substances. For instance, in April 2024, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, received approval from the U.S. Food and Drug Administration for FASENRA (benralizumab) as an add-on maintenance treatment for children aged 6 to 11 years with severe asthma characterized by an eosinophilic phenotype. This antibody aims to reduce asthma exacerbations and improve symptom control by targeting and eliminating eosinophils. Fasenra is administered by subcutaneous injection once every four weeks for the first three doses, followed by once every eight weeks, with pediatric dosing adjusted according to body weight.

In January 2025, Molex LLC, a US-based consumer electronics company, acquired Vectura Group plc for an undisclosed sum. Through this acquisition, Molex LLC intends to expand its inhalation drug delivery capabilities and reinforce its position as a leading provider of comprehensive solutions for respiratory and non-respiratory therapies. Vectura Group Services Limited is a UK-based company developing a pediatric asthma treatment, a smart budesonide delivery system known as VR647.

Major players in the pediatric asthma treatment market are Pfizer Inc., Merck And Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Lupin Limited, Zydus Lifesciences Ltd., and ECU Health.

North America was the largest region in the pediatric asthma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric asthma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pediatric asthma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pediatric asthma treatment market consists of sales of nebulizers and soft-mist inhalers, oral medications, biologic injectables, and smart monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The pediatric asthma treatment market research report is one of a series of new reports that provides pediatric asthma treatment market statistics, including pediatric asthma treatment global market size, regional shares, competitors with pediatric asthma treatment market share, detailed pediatric asthma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric asthma treatment industry. The pediatric asthma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric asthma treatment involves medical care and therapeutic approaches aimed at managing and alleviating asthma symptoms in children. This includes medications, lifestyle changes, and monitoring techniques to reduce inflammation, prevent asthma attacks, and enhance respiratory function.

The primary types of pediatric asthma treatment include long-term control medications, quick-relief medications, and other categories. Long-term control medications are drugs taken daily over a prolonged period to decrease inflammation, prevent symptoms, and maintain stable lung function. This group includes inhaled corticosteroids, long-acting beta agonists, leukotriene modifiers, antihistamines, and biologics. These medications are administered via various routes such as oral, nasal, and injectable. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used in different settings including hospitals, clinics, home care, and other healthcare environments.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.